The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Stifel Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $64
Stifel analyst Dae Gon Ha maintains $Intellia Therapeutics(NTLA.US)$ with a buy rating, and adjusts the target price from $80 to $64.According to TipRanks data, the analyst has a success rate of 46.0%
Expert Outlook: Intellia Therapeutics Through The Eyes Of 7 Analysts
Intellia Therapeutics Is Maintained at Buy by Stifel
Express News | Intellia Therapeutics Inc : Stifel Cuts Target Price to $64 From $80
Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Latest 6.7% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures